# Lecanemab with MRI monitoring

Source: https://onco.cc/pairings/da-pair-lecanemab-mri/  
OnCo record `da-pair-lecanemab-mri` (Pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Amyloid antibodies are used with scheduled MRI checks for ARIA, not as a standalone infusion without imaging follow-up.

## Summary

This pairing is a teaching node: the medicine and the scan belong together. It is not a local protocol.

## Fields

- Kind: Pairing
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Pairs: Lecanemab + Brain MRI
- Type: diagnostic-therapeutic
- Rationale: ARIA monitoring on MRI is part of using an amyloid antibody, not an optional extra.
- Evidence: The US lecanemab label requires MRI monitoring for ARIA. See the FDA approval communication.

## Sources

- FDA Leqembi: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)
- technologies: [Brain MRI](https://onco.cc/technologies/da-tech-mri/)
- drugs: [Lecanemab](https://onco.cc/drugs/da-lecanemab/)
- terms: [ARIA](https://onco.cc/terms/da-term-aria/)

---
JSON: https://onco.cc/api/v1/entities/da-pair-lecanemab-mri.json